Cilostazol Protects Against Changes Caused by Streptozotocin-induced Diabetic Retinopathy

Overview

Journal Arq Bras Oftalmol

Specialty Ophthalmology

Date 2022 Jul 20

PMID 35857986

Authors

Diego Jose Schebelski

Leandro Lipinski

Carlos Augusto Moreira Junior

Adriana Yuriko Koga

Bruna Carletto

Mario M Montemor

Paulo Vitor Farago

Ricardo Zanetti Gomes

Affiliations

Soon will be listed here.

Abstract

Purpose: This study investigates the protective effect of cilostazol on the development and evolution of diabetic retinopathy in rats.

Methods: Sixty male rats were divided into four groups: untreated nondiabetic rats, untreated diabetic rats, cilostazol-treated nondiabetic rats, and cilostazol-treated diabetic rats. The thickness of the internal limiting membrane to the outer limiting membrane, inner plexiform layer, inner nuclear layer, and outer nuclear layer were measured. The number of cell nuclei per 50-μm length in retinal sections was counted to quantify the degree of retinal cell loss.

Results: The number of nuclei in the ganglion cell layer was significantly higher in untreated nondiabetic rats (p<0.05). The mean number of nuclei in the cilostazol-treated nondiabetic rats was significantly higher than that in the cilostazol-treated diabetic rats (p<0.05). The cilostazol-treated nondiabetic rats had a significantly higher mean nuclei count in the inner nuclear layer and inner plexiform layer as compared with the other groups (p<0.05). The total mean retinal thickness of the cilostazol-treated nondiabetic rats was significantly higher than that of cilostazol-treated diabetic rats and untreated diabetic rats (p<0.05).

Conclusion: By decreasing the loss of ganglion cells and reducing the sensorineural atrophy in the internal retinal layers, cilostazol had a protective effect against changes caused by diabetic retinopathy in diabetic rats.

References

Yeh P, Huang Y, Chang S, Wang L, Yang C, Yang W . Cilostazol Attenuates Retinal Oxidative Stress and Inflammation in a Streptozotocin-Induced Diabetic Animal Model. Curr Eye Res. 2018; 44(3):294-302. DOI: 10.1080/02713683.2018.1542734. View

Hughes W . Quantitation of ischemic damage in the rat retina. Exp Eye Res. 1991; 53(5):573-82. DOI: 10.1016/0014-4835(91)90215-z. View

Martin P, Roon P, Van Ells T, Ganapathy V, Smith S . Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004; 45(9):3330-6. DOI: 10.1167/iovs.04-0247. View

Semeraro F, Cancarini A, dellOmo R, Rezzola S, Romano M, Costagliola C . Diabetic Retinopathy: Vascular and Inflammatory Disease. J Diabetes Res. 2015; 2015:582060. PMC: 4475523. DOI: 10.1155/2015/582060. View

Schafer A, Bauersachs J . Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008; 6(1):52-60. DOI: 10.2174/157016108783331295. View

Natarajan A, Zaman A, Marshall S . Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res. 2008; 5(2):138-44. DOI: 10.3132/dvdr.2008.023. View

Liu J, Chuang T, Chen J, Lee C, Hsieh C, Lin T . Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products. Endocrine. 2015; 49(3):703-10. PMC: 4512567. DOI: 10.1007/s12020-015-0545-6. View

Jung K, Kim J, Park H, Park C . Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. J Pharmacol Exp Ther. 2013; 345(3):457-63. DOI: 10.1124/jpet.113.203067. View

Scarinci F, Nesper P, Fawzi A . Deep Retinal Capillary Nonperfusion Is Associated With Photoreceptor Disruption in Diabetic Macular Ischemia. Am J Ophthalmol. 2016; 168:129-138. PMC: 4969199. DOI: 10.1016/j.ajo.2016.05.002. View

10.

Leasher J, Bourne R, Flaxman S, Jonas J, Keeffe J, Naidoo K . Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016; 39(9):1643-9. DOI: 10.2337/dc15-2171. View

11.

Miller J . Vascular endothelial growth factor and ocular neovascularization. Am J Pathol. 1997; 151(1):13-23. PMC: 1857918. View

12.

Zheng Y, He M, Congdon N . The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012; 60(5):428-31. PMC: 3491270. DOI: 10.4103/0301-4738.100542. View

13.

Weintraub W . The vascular effects of cilostazol. Can J Cardiol. 2006; 22 Suppl B:56B-60B. PMC: 2780845. DOI: 10.1016/s0828-282x(06)70987-4. View

14.

Asal N, Wojciak K . Effect of cilostazol in treating diabetes-associated microvascular complications. Endocrine. 2017; 56(2):240-244. DOI: 10.1007/s12020-017-1279-4. View

15.

Goldberg R . Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009; 94(9):3171-82. DOI: 10.1210/jc.2008-2534. View

16.

Gustavsson C, Agardh C, Hagert P, Agardh E . Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion. Retina. 2008; 28(4):645-52. DOI: 10.1097/IAE.0b013e31815ec32d. View

17.

Kim H, Lee S, Kim Y, Oh J, Ohn Y . The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. Doc Ophthalmol. 2016; 133(1):49-60. DOI: 10.1007/s10633-016-9550-1. View

18.

Iwama D, Miyamoto K, Miyahara S, Tamura H, Tsujikawa A, Yamashiro K . Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. J Thromb Haemost. 2007; 5(4):818-25. DOI: 10.1111/j.1538-7836.2007.02425.x. View

19.

Lima V, Cavalieri G, Lima M, Nazario N, Lima G . Risk factors for diabetic retinopathy: a case-control study. Int J Retina Vitreous. 2016; 2:21. PMC: 5088444. DOI: 10.1186/s40942-016-0047-6. View

20.

Lai A, Lo A . Animal models of diabetic retinopathy: summary and comparison. J Diabetes Res. 2013; 2013:106594. PMC: 3826427. DOI: 10.1155/2013/106594. View